Silmitasertib sodium salt Inhibitor

Name: Silmitasertib sodium salt Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5754751
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754751

Silmitasertib sodium salt is a potent and orally bioavailable, highly selective inhibitor of CK2(IC50 of 1nM, CK2alpha). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Silmitasertib sodium salt, Inhibitor

Full Product Name

Silmitasertib sodium salt

Product Synonym Names

CX-4945 sodium salt

Form/Format

Solid. Powder

Purity/Purification

99.49%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

371.75

Solubility

H2O: 16.67mg/mL (44.84mM) Need ultrasonic
DMSO: 6mg/mL (16.13mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C19H11ClN3NaO2

SMILES

[Na+].[O-]C(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21

CAS Number

1309357-15-0

Target & IC50

CK2alpha: ic50
CK2alpha': ic50
CK2
Autophagy

In Vitro

Silmitasertib (CX-4945) (25 or 75mg/kg, p.o.) is well tolerated. It showed robust antitumor activity with concomitant reductions of the mechanism-based biomarker phospho-p21 (T145) in murine xenograft models[1].

Product Categories/Family for Silmitasertib sodium salt, inhibitor

Metabolism; Stem Cells; Autophagy

Product References and Citations for Silmitasertib sodium salt, inhibitor

Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.
Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.
Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of beta-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203.
Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of beta-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203.
Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-kappaB. Oncotarget. 2016 Jan 12;7(2):1323-40.
Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-kappaB. Oncotarget. 2016 Jan 12;7(2):1323-40.
Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment,of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.
Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment,of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.

Other Notes

Small volumes of Silmitasertib sodium salt, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Silmitasertib sodium salt purchase

MBS5754751 is an inhibitor targeting Silmitasertib sodium salt.